Compare Cytokinetics Inc (CYTK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Simon Property Group Inc — how do they compare? Cytokinetics Inc trades at $81.69 (market cap $11.12B), while Simon Property Group Inc trades at $222.5 (market cap $71.76B). The key difference: Simon Property Group Inc is far larger — about 6.5× Cytokinetics Inc's market cap, and Simon Property Group Inc pays a 3.98% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SPG | |
|---|---|---|
Market Cap | $11.12B | $71.76B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $227.56 |
52-Week Low | $33.23 | $159.93 |
Enterprise Value | $11.59B | $100.24B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
SPG trades at $219.49, up 0.33% on the day, with a bearish technical signal despite bullish moving averages. The stock shows strong fundamentals with a 72.7% net income margin in 2025 and consistent earnings beats. Recent news highlights robust Q1 2026 results and a 4% dividend yield, though some analysts express caution on valuation. Cash flow trends indicate increased capital expenditures, with net cash flow turning negative in 2025.
Outlook remains mixed: strong leasing activity and raised FFO guidance support upside, but high debt levels and e-commerce risks weigh on sentiment. Analysts are predominantly neutral with a $214.40 consensus target, slightly below current price. Investors should balance income appeal against valuation concerns and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
